Your browser doesn't support javascript.
CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2.
Hoffmann, Donata; Corleis, Björn; Rauch, Susanne; Roth, Nicole; Mühe, Janine; Halwe, Nico Joel; Ulrich, Lorenz; Fricke, Charlie; Schön, Jacob; Kraft, Anna; Breithaupt, Angele; Wernike, Kerstin; Michelitsch, Anna; Sick, Franziska; Wylezich, Claudia; Hoffmann, Bernd; Thran, Moritz; Thess, Andreas; Mueller, Stefan O; Mettenleiter, Thomas C; Petsch, Benjamin; Dorhoi, Anca; Beer, Martin.
  • Hoffmann D; Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.
  • Corleis B; Institute of Immunology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.
  • Rauch S; CureVac AG, Tübingen, Germany.
  • Roth N; CureVac AG, Tübingen, Germany.
  • Mühe J; CureVac AG, Tübingen, Germany.
  • Halwe NJ; Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.
  • Ulrich L; Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.
  • Fricke C; Institute of Immunology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.
  • Schön J; Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.
  • Kraft A; Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.
  • Breithaupt A; Department of Experimental Animal Facilities and Biorisk Management, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.
  • Wernike K; Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.
  • Michelitsch A; Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.
  • Sick F; Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.
  • Wylezich C; Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.
  • Hoffmann B; Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.
  • Thran M; CureVac AG, Tübingen, Germany.
  • Thess A; CureVac AG, Tübingen, Germany.
  • Mueller SO; CureVac AG, Tübingen, Germany.
  • Mettenleiter TC; Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Greifswald-Insel Riems, Germany.
  • Petsch B; CureVac AG, Tübingen, Germany.
  • Dorhoi A; Institute of Immunology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany. anca.dorhoi@fli.de.
  • Beer M; Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany. martin.beer@fli.de.
Nat Commun ; 12(1): 4048, 2021 06 30.
Article in English | MEDLINE | ID: covidwho-1290662
ABSTRACT
The ongoing SARS-CoV-2 pandemic necessitates the fast development of vaccines. Recently, viral mutants termed variants of concern (VOC) which may escape host immunity have emerged. The efficacy of spike encoding mRNA vaccines (CVnCoV and CV2CoV) against the ancestral strain and the VOC B.1.351 was tested in a K18-hACE2 transgenic mouse model. Naive mice and mice immunized with a formalin-inactivated SARS-CoV-2 preparation were used as controls. mRNA-immunized mice develop elevated SARS-CoV-2 RBD-specific antibody and neutralization titers which are readily detectable, but significantly reduced against VOC B.1.351. The mRNA vaccines fully protect from disease and mortality caused by either viral strain. SARS-CoV-2 remains undetected in swabs, lung, or brain in these groups. Despite lower neutralizing antibody titers compared to the ancestral strain BavPat1, CVnCoV and CV2CoV show complete disease protection against the novel VOC B.1.351 in our studies.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / Spike Glycoprotein, Coronavirus / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2021 Document Type: Article Affiliation country: S41467-021-24339-7

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / Spike Glycoprotein, Coronavirus / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2021 Document Type: Article Affiliation country: S41467-021-24339-7